Up next

Autoplay

Ovarian Cancer Subtypes May Predict Response to Bevacizumab

1 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Sean Dowdy, M.D., a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. For more information

Show more
0 Comments sort Sort By

Up next

Autoplay